FDA warns sellers of semaglutide, tirzepatide and retatrutide labelled "for research purposes"

FDA's page on unapproved GLP-1 drugs, current as of 1 September 2026, says the agency has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that were "falsely labeled" for research purposes or not for human consumption ^[1]. FDA says these products were sold directly to consumers for human use, with dosing instructions, and urges consumers not to purchase them because they are of unknown quality ^[1].

The same page lists wider problems FDA has seen with GLP-1 products outside the approved supply: counterfeit Ozempic, fraudulent compounded semaglutide and tirzepatide carrying the names of pharmacies that did not make them, and adverse event reports that may be linked to dosing errors, some requiring hospitalisation ^[1]. As of 31 May 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and it notes that it is not always possible to tell whether the drug caused a given event ^[1].

On 31 March 2026 FDA's Center for Drug Evaluation and Research wrote to Gram Peptides of Rancho Santa Fe, California, after reviewing its website from January to March 2026 ^[2]. The letter covers retatrutide, which the site called "GLP-1-R peptide", tirzepatide, called "GLP-2 peptide", and bacteriostatic water for injection ^[2]. FDA said the products were unapproved new drugs and that shipping them across state lines violated sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act ^[2].

On 24 August 2026 FDA wrote to Royal Peptides LLC of Boynton Beach, Florida, after a July 2026 review of its website ^[3]. That letter names tirzepatide, semaglutide, retatrutide, SS-31 (elamipretide), PT-141, tesamorelin and a tesamorelin and ipamorelin blend as unapproved new drugs, citing the same sections of the Act ^[3]. The site described retatrutide and tirzepatide in terms of weight reduction figures from clinical studies, and FDA quoted those passages as evidence of intended use ^[3].

Both letters asked for a written response within 15 working or business days, and both warned that failure to address the violations could lead to legal action including seizure and injunction ^[2][3].

In the Gram Peptides letter FDA wrote that despite labelling for "Research Use Only" and "not intended for human consumption", evidence from the website "establishes that your products are intended to be drugs for human use" ^[2]. It treated the bacteriostatic water as a drug too, because selling it alongside peptides that need reconstitution showed it was meant to be used for injection ^[2].

The Royal Peptides letter makes the same point in a footnote and adds a further detail. FDA noted that the company offered bacteriostatic water together with a "peptide guide" and a "peptide calculator", which it said collectively provide the means to prepare an injectable drug for human administration ^[3]. In both cases FDA looked at the whole website, not only the label, to decide what the products were for.

No. On retatrutide FDA approval, the agency's position as of September 2026 is that retatrutide and cagrilintide are not components of any FDA-approved drug, have not been found safe and effective for any condition, and cannot be used in compounding under federal law ^[1]. FDA says it has warned telehealth companies for marketing retatrutide directly to consumers, ingredient distributors for selling it to compounders, and outsourcing facilities for repackaging it ^[1].

Searches for a retatrutide FDA approval date usually rest on company and press reports about future filings. We do not report those here, because we found no FDA publication about a retatrutide application. For retatrutide FDA approval status 2026, the verifiable answer is that it is not approved. How it compares with tirzepatide in trials is covered in retatrutide vs tirzepatide.

Semaglutide and tirzepatide are different: both are active ingredients in FDA-approved medicines, including Ozempic, Wegovy, Mounjaro and Zepbound ^[4], which our GLP-1 brand names guide lists. The warning letters concern unapproved versions sold outside that system, not the approved products.

A "research use only" label is not treated by FDA as a legal exemption when the seller's website points to human use. Our US legal status guide covers the federal rules in more detail, and the guide to how to spot a fake peptide supplier explains the warning signs FDA and other regulators describe. The retatrutide price comparison records what sellers list; a listing on PepFinder is not a statement that a product is lawful or safe to use.